130
Participants
Start Date
May 31, 2012
Primary Completion Date
May 31, 2014
Study Completion Date
May 31, 2014
pGM169/GL67A
5ml Gene Product/Lipid Vector pGM169/GL67A nebulised; 2ml nasal application of pGM169/GL67A in addition to 5ml nebulised gene product (Nasal Subgroup)
Placebo
5ml Nebulised non-active placebo; 2ml nasal administration of non-active placebo (nasal subgroup)
Western General Hospital, Edinburgh
Royal Hospital for Sick Children, Edinburgh
Royal Brompton Hospital, London
University of Edinburgh
OTHER
University of Oxford
OTHER
Royal Brompton & Harefield NHS Foundation Trust
OTHER
Imperial College London
OTHER